The present disclosure relates generally to a system for treating occlusions in a body lumen. The system is useful for a chronic total coronary occlusion (“CTO”), a partial coronary occlusion, or a kidney stone in ureter, in order to restore normal flow in a lumen (e.g., the artery or the ureter).
In angioplasty or peripheral angioplasty procedures, an angioplasty balloon is used to dilate a lesion (e.g., calcified lesion) and restore normal blood flow in the artery. In some examples, an angioplasty balloon is advanced into the vasculature (e.g., along a guide wire) until the balloon is aligned with calcified plaques. The balloon is then pressurized with a fluid to expand the vessel to permit blood flow.
More recently, a system has been developed wherein electrodes are disposed in the angioplasty balloon. Once the balloon is initially positioned adjacent a blockage, a series of high voltage pulses are applied to the electrodes in a manner to generate a series of shock waves. The shock waves act to crack calcified lesions. Once the lesions are cracked, the balloon can be inflated, in a more gentle fashion, to expand the vessel and improve circulation.
Further information about the latter type of device can be found in U.S. Pat. Nos. 8,856,371; 8,747,416 and 9,642,673. Shock wave technology has also been developed for treating heart valves (U.S. 2018/0098779) and for guide wire designs (U.S. Pat. No. 9,730,715). U.S. Patent Publication 2018/03640482 describes a forward directed shock wave device. Each of these patent documents is incorporated herein by reference.
Arteries are sometimes totally or partially occluded, for example, with thrombus, plaque, fibrous plaque, and/or calcium deposits. When this condition is present, the physician must first cross the occlusion, and then feed the angioplasty balloon and/or other tools down the artery to the desired location of blockage to perform the desired procedure. However, in some instances (e.g., CTO), the occlusion is so tight and solid, making it difficult to cross the treatment device into the true lumen of the distal vessel.
CTOs remain a challenge in percutaneous coronary interventions, as well as a challenge for the periphery, causing critical limb ischemia and amputations. First, many of the currently available equipment are incapable of physically crossing the tough proximal cap or distal cap (retrograde approach) of the CTO. In some instances, attempting to penetrate the CTO cap using soft guide wire causes buckling (e.g., deflecting the guidewire to a subintimal passage or collateral branch). On the other hand, stiffer guide wires may damage the artery wall when forced against the CTO. Moreover, some currently available equipment operate by generating strong mechanical vibrations to break the CTO, but the intensity of the vibration may damage the artery wall and make the system less durable and more difficult to control.
Similar issues are present for occlusions formed in other parts of the body, for example, kidney stones in a ureter.
The invention provides a system for treating an occlusion such as CTO or kidney stones within a lumen such as a blood vessel or a ureter. In some embodiments, the system comprises an insulated outer sheath, an elongated conductive tube, wherein the insulated outer sheath is circumferentially mounted around the elongated conductive tube, and an insulated wire having a helically coiled portion at a distal end of the insulated wire. The coiled portion includes an exposed distal tip. A distal portion of the elongated conductive tube is circumferentially mounted around the distal coiled portion of the insulated wire. When a voltage is applied across the insulated wire and the elongated conductive tube, a current is configured to flow from the exposed distal tip of the insulated wire to the elongated conductive tube to ionize the fluid around it and generate a plurality of cavitation bubbles and bubble-associated dynamics (collapses, jets, etc.).
In some embodiments, a method for treating an occlusion within a lumen such as a blood vessel or a ureter comprises advancing a treatment device within the lumen to contact the occlusion. The treatment device comprises: an insulated outer sheath; an elongated conductive tube, wherein the insulated outer sheath is circumferentially mounted around the elongated conductive tube; and an insulated wire having a helically coiled portion at a distal end of the insulated wire, wherein the coiled portion includes an exposed distal tip and wherein a distal portion of the elongated conductive tube is circumferentially mounted around the distal coiled portion of the insulated wire. The method further comprises injecting conductive fluid (i.e. physiological saline, mixture of saline and angiographic contrast dyes, etc.) toward a distal end of the treatment device; and applying a voltage across the insulated wire and the elongated conductive tube to cause a current to flow from the exposed distal tip of the insulated wire to the elongated conductive tube to generate a plurality of cavitation bubbles and bubble-associated dynamics (collapses, jets, etc.).
In some embodiments, a system for treating an occlusion within a body lumen is disclosed. The system includes an insulated wire having a helically coiled portion near the distal end thereof, and with the distal tip of the insulated wire having a portion of the insulation removed to define an electrode. The system further includes an elongated central electrode with the distal end thereof being received within the helically coiled portion of the insulated wire. In one preferred embodiment, the system further includes an insulated tube located about the distal end of the central electrode and within the helically coiled portion of the insulated wire. Finally, a tubular outer shell is provided for covering the coiled portion of the insulated wire. The proximal ends of the insulated wire and the central electrode are connectable to the terminals of an electrical pulse generator so that in use, when voltage pulses are applied to the central electrode and the insulated wire, a series of cavitation bubbles are created between the electrode of the insulated wire and the central electrode.
The following description sets forth exemplary methods, parameters, and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
Described herein are exemplary systems and methods for treating an occlusion such as CTO or kidney stones in a ureter. In according with some embodiments, the treatment system includes a forward bubble generating tip to be advanced within the lumen to contact the occlusion. The forward bubble generating tip includes electrodes that, when provided with a relatively low-voltage and high-PRF (pulse repetition rate) generator, form plasma arcs that in turn lead to cavitation bubbles. The cavitation bubbles create mechanical vibrations, turbulence, jets, and/or forceful collapses to break the occlusion. The output of the generator is configured to be sufficient for creating electro-hydraulic discharge and cavitation bubbles for effectively drilling, but not enough to create a powerful shock wave that may compromise the durability of the system. As such, the mechanical vibrations are relatively gentle compared to currently available equipment. Accordingly, the treatment system is less likely to cause damage to the lumen wall (e.g., vessel wall) and is easier to control and more durable.
As depicted, the distal edge of the insulated layer 206 is aligned with the distal edge of the elongated conductive tube 208. Further, the distal edge of the elongated conductive tube 208 extends beyond the helically coiled wire portion 202 by distance B. In some examples, the distance B ranges from 0 mm (i.e., the distal end of the coiled portion is aligned with the distal edge of the elongated tube) to 0.5 mm. In some examples, one or more of the other factors that affect the efficiency of the operation, such as the flow rate of the conductive fluid, the applied voltage, the shape and composition of the occlusion, are taken into account when setting distance B to achieve an optimal configuration. This relative positioning of the helically coiled wire portion 202 and the distal edges of the insulated layer 206 and elongated conductive tube 208 ensures safety to the surrounding tissue, protects the catheter from the vibrations emitting from the tip, and causes the mechanical vibrations to be generated in a forward-facing direction, thus increasing the intensity, and thus the effectiveness, of the treatment system in breaking down the occlusion. Further, the forward-facing mechanical vibrations, along with the continuous flow rate in the forward direction, result in drilling of holes that are consistent (e.g., in size, in shape), thus making the treatment system easier to operate. In some examples, the treatment system is configured to drill holes of around 1 mm in diameter in calcified materials.
In some examples, the flow of saline or saline/angiographic contrast mix is adjusted to avoid over-heating issues and control drilling efficiency and rate. In some examples, the flow rate is configured to be in the range of 1 to 30 mL/min to improve breakability of calcified structures.
In an exemplary operation, when the proximal ends of the insulated wires 110 and 112 are connected to the negative port and positive port of a generator, respectively, a current flows from the distal end 210 of the insulated wire 112 to the elongated conductive tube 208. The current can cause a plurality of plasma arcs to be formed between the distal end 210 of the insulated wire 112 and the inner diameter of the elongated conductive tube 208 (e.g., across the distal edge 203 of the insulated layer 206 or through the holes 204 in 206). The plasma arcs lead to cavitation bubbles in a controlled fashion (one at a time, at a particular rate), which in turn lead to mechanical vibrations, and other bubble dynamics-related effects such as collapses, turbulence, jetting, etc. in the conductive fluid (e.g., via the expansion and collapse of the bubbles). The mechanical vibrations serve to break or chip away the occlusion. As compared to the generators used in the prior art shock wave generation systems mentioned above, the generator for this system is configured to generate lower-voltage pulses at a higher pulse repetition rate in order to minimize the strength of the shock waves and optimize and maximize bubble growth and collapse. For example, in the prior art systems, each pulse might be about 3000 volts with a 1 Hz repetition rate. In this system, the voltage can be under 1000 volts with the repetition rates ranging from 14 to 200 Hz. In a preferred embodiment, repetition rates can as high as 800 Hz.
As the plasma arcs cause erosion to the electrodes in operation, the helically coiled wire portion 202 and/or the insulation over the coiled wire portion can disintegrate and shorten over time. Similarly, the insulation layer 206 and the distal edge of the elongated conductive tube 208 can disintegrate due to use. The rates at which the coiled wire portion, the insulated layer, and the elongated conductive tube disintegrate can vary based on physical characteristics of each component (e.g., the diameter of the wire, the property of the wire, the thickness of the insulation layer), the polarities of the applied voltage, the magnitude of the applied voltage, etc. For example, a wire that is relatively thin, connected to a relatively high voltage supply, and/or connected to the positive voltage port would erode faster. In some instances, before the helically coiled wire portion 202 experiences extensive usage, the plasma arcs are generated across the distal edge 203 of the insulated layer 206. However, as the helically coiled wire portion 202 shortens due to usage, the distance between the distal end 210 of the insulated wire 112 and the distal edge of the insulated layer 206 increases. Due to the increased distance, plasma arcs are no longer generated across the distal edge 203 of the insulated layer 206. Instead, as current flows from the distal end 210 of the helically coiled wire portion 202 to inner diameter of the elongated conductive tube 208, plasma arcs are generated across one of the holes 204 (e.g., the hole located closest to the distal end 210 of the shortened helically coiled wire portion) in the insulated layer 206. As shown in
In some examples, various parameters can be adjusted during the operation to slow down or even out the erosion of the electrodes. For example, the frequency of bubble generation/emission (pulses per minute) can be adjusted to control the tip erosion, durability and drilling time. The frequency of bubble generation can be controlled by reducing the capacitance (so a capacitance switch can change the speed on demand), or by reducing the current power supply. As another example, the applied voltage can be adjusted as a function of drilling time to control the emitter erosion and device durability while maintaining the frequency constant as a function of drilling time. Further, polarity of the electrodes can be reversed for a period of time equivalent to a fraction of the treatment time (e.g., 10% to 100% of the time) while maintaining the voltage and frequency constant as a function of drilling time in order to control electrode wear and improve device durability. Further still, the thickness of the wire insulation can be chosen to control the durability of the wire.
U.S. Pat. No. 10,226,265, incorporated by reference, teaches various approaches for switching polarity of electrode pairs positioned in a conductive fluid. Those types of approaches can be utilized with the subject device. In particular, to maintain peak sonic output, the spark gap should be constant. As the electrodes erode away, the gap can vary. To compensate for this variation in gap size, the polarity on the electrodes can be reversed. The polarity reversal frequency can be used to help control variations in the length of the spark gap. It is possible to tune the polarity reversal frequency based on the power being delivered, wire diameter and insulator thickness. It is also possible to have the generator detect the power degradation and automatically reverse the polarity on the electrodes.
In use, a guidewire can be advanced through the central open region in the device and towards the hole drilled or being drilled in the occlusion. For example, the guidewire can be advanced through the drilled hole to guide the advancement of the treatment system, which continues drilling until the occlusion is crossed. In some examples, the guidewire can be advanced through the elongated conductive tube (e.g., from saline inlet 402), more specifically, through the center of the coiled portion of the bubble generating tip. After the occlusion is crossed, the forward bubble generating tip can be withdrawn, while the guidewire can remain to allow the access of other tools such as angioplasty or Lithoplasty™ balloons using over the wire entry. Lithoplasty is the trademark of assignee directed to its intravascular lithotripsy (shock wave) catheters. As discussed below, after the hole is drilled, an angioplasty balloon catheter can be advanced through the drilled hole to a distal end of the occlusion and aligned with the occlusion.
As an alternative, the angioplasty balloon is a lithotripsy balloon and a shock wave generator may be disposed within the balloon 602. The shock wave generator may take the form of, for example, a pair of electrodes. When the balloon 602 is aligned with the distal end of the occlusion and a high voltage pulse is applied across the electrodes, a shock wave is formed that propagates through the fluid and impinges upon the wall of the balloon and the occlusion. Repeated shock waves break up the occlusion without damaging surrounding soft tissues. In some examples, the shock waves can be generated along an axis perpendicular to the axis of the catheter (instead of being forwardly directed) so that they treat different parts of the occlusion. The angioplasty balloon 602 can then be expanded to further open up the lumen. As depicted in
The distal end of the central electrode 720 is received within the coiled portion 702 of the insulated wire. In the preferred embodiment, an insulated tube 706 surrounds the distal end of the central electrode. The insulated tube includes a plurality of holes 704 that provide additional pathways for conducting current as the coiled portion of the insulated wire erodes during use. In a preferred embodiment, an annular channel 730 is formed between the outer surface of the insulated tube 706 and the inner surface of the coiled portion 702. This channel can be used to supply conductive fluid to the distal tip of the device. Since the wire 712 is insulated, it may be possible to configure the device without the insulated tube 706.
A cylindrical outer shell 724 surrounds the distal end of the device. The shell can be formed from a metal such as stainless steel. Alternatively, the shell could be made from a non-metal such as Polyether ether ketone (PEEK) or a polyimide-based plastics such as Vespel198 . The material should be heat resistant and provide some stiffness for crossing the occlusion. The proximal end portion of the outer shell (728), is formed from a more flexible material to facilitate advancement of the device through the circulatory system.
The embodiment of
As in the previous embodiments, during operation, the end of the coiled portion of the insulate wire will typically erode. As the wire erodes, the point at which the cavitation bubbles are generated moves circumferentially about the periphery of the central electrode. As noted above, the holes 704 in the insulated tube 706 provide sequential pathways for the current as the coiled wire erodes.
In a preferred embodiment, the central electrode 720 is removably mounted within the device. In use, after the occlusion has been opened, the central electrode can be removed providing a channel for insertion of a guidewire or other device for further treatment.
It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications, alterations and combinations can be made by those skilled in the art without departing from the scope and spirit of the invention. For example, the foregoing principles can applied to treat occlusions formed in any part of the body. Any of the variations of the various treatment systems disclosed herein can include features described by any other treatment systems or combination of treatment systems herein. Furthermore, any of the methods can be used with any of the treatment systems disclosed. Accordingly, it is not intended that the invention be limited, except as by the appended claims. For all of the variations described above, the steps of the methods need not be performed sequentially.
This application claims priority to U.S. Patent Application Ser. No. 62/688,110 filed Jun. 21, 2018, the entire disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3051862 | Johnm | Aug 1962 | A |
3413976 | Roze | Dec 1968 | A |
3785382 | Schmidt-Kloiber et al. | Jan 1974 | A |
3902499 | Shene | Sep 1975 | A |
4027674 | Tessier et al. | Jun 1977 | A |
4030505 | Tessier | Jun 1977 | A |
4662126 | Malcolm | May 1987 | A |
4671254 | Fair | Jun 1987 | A |
4685458 | Leckrone | Aug 1987 | A |
4809682 | Forssmann et al. | Mar 1989 | A |
4813934 | Engelson et al. | Mar 1989 | A |
4870953 | Don Micheal | Oct 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4900303 | Lemelson | Feb 1990 | A |
4994032 | Sugiyama et al. | Feb 1991 | A |
5009232 | Hassler et al. | Apr 1991 | A |
5046503 | Schneiderman | Sep 1991 | A |
5057103 | Davis | Oct 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5061240 | Cherian | Oct 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5103556 | Filip | Apr 1992 | A |
5103804 | Abele et al. | Apr 1992 | A |
5125928 | Parins et al. | Jun 1992 | A |
5150717 | Rosen | Sep 1992 | A |
5152767 | Sypal et al. | Oct 1992 | A |
5152768 | Bhatta | Oct 1992 | A |
5154722 | Filip | Oct 1992 | A |
5176675 | Watson et al. | Jan 1993 | A |
5195508 | Muller et al. | Mar 1993 | A |
5245988 | Einars et al. | Sep 1993 | A |
5246447 | Rosen et al. | Sep 1993 | A |
5254121 | Manevitz et al. | Oct 1993 | A |
5281231 | Rosen et al. | Jan 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5321715 | Trost | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5336234 | Vigil et al. | Aug 1994 | A |
5362309 | Carter | Nov 1994 | A |
5364393 | Auth et al. | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5395335 | Jang | Mar 1995 | A |
5417208 | Winkler | May 1995 | A |
5425735 | Rosen et al. | Jun 1995 | A |
5472406 | de la Torre et al. | Dec 1995 | A |
5582578 | Zhong et al. | Dec 1996 | A |
5603731 | Whitney | Feb 1997 | A |
5609606 | O'Boyle | Mar 1997 | A |
5662590 | de la Torre et al. | Sep 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5735811 | Brisken | Apr 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5931805 | Brisken | Aug 1999 | A |
6007530 | Dornhofer et al. | Dec 1999 | A |
6033371 | Torre et al. | Mar 2000 | A |
6080119 | Schwarze et al. | Jun 2000 | A |
6083232 | Cox | Jul 2000 | A |
6113560 | Simnacher | Sep 2000 | A |
6186963 | Schwarze et al. | Feb 2001 | B1 |
6210404 | Shadduck | Apr 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6217531 | Reitmajer | Apr 2001 | B1 |
6267747 | Samson et al. | Jul 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6287272 | Brisken et al. | Sep 2001 | B1 |
6352535 | Lewis et al. | Mar 2002 | B1 |
6367203 | Graham et al. | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6406486 | De La Torre et al. | Jun 2002 | B1 |
6514203 | Bukshpan | Feb 2003 | B2 |
6524251 | Rabiner et al. | Feb 2003 | B2 |
6589253 | Cornish et al. | Jul 2003 | B1 |
6607003 | Wilson | Aug 2003 | B1 |
6638246 | Naimark et al. | Oct 2003 | B1 |
6652547 | Rabiner | Nov 2003 | B2 |
6689089 | Tiedtke et al. | Feb 2004 | B1 |
6736784 | Menne et al. | May 2004 | B1 |
6740081 | Hilal | May 2004 | B2 |
6755821 | Fry | Jun 2004 | B1 |
6855123 | Nita | Feb 2005 | B2 |
6989009 | Lafontaine | Jan 2006 | B2 |
7087061 | Chernenko | Aug 2006 | B2 |
7241295 | Maguire | Jul 2007 | B2 |
7505812 | Eggers et al. | Mar 2009 | B1 |
7569032 | Naimark et al. | Aug 2009 | B2 |
7873404 | Patton | Jan 2011 | B1 |
7951111 | Drasler et al. | May 2011 | B2 |
8162859 | Schultheiss et al. | Apr 2012 | B2 |
8556813 | Cioanta et al. | Oct 2013 | B2 |
8574247 | Adams et al. | Nov 2013 | B2 |
8709075 | Adams | Apr 2014 | B2 |
8728091 | Hakala et al. | May 2014 | B2 |
8747416 | Hakala et al. | Jun 2014 | B2 |
8856371 | Kariti et al. | Oct 2014 | B2 |
8888788 | Hakala et al. | Nov 2014 | B2 |
8956371 | Hawkins et al. | Feb 2015 | B2 |
8956374 | Hawkins et al. | Feb 2015 | B2 |
9005216 | Hakala et al. | Apr 2015 | B2 |
9011462 | Adams et al. | Apr 2015 | B2 |
9011463 | Adams et al. | Apr 2015 | B2 |
9044618 | Hawkins et al. | Jun 2015 | B2 |
9044619 | Hawkins et al. | Jun 2015 | B2 |
9198825 | Katragadda | Dec 2015 | B2 |
9333000 | Hakala et al. | May 2016 | B2 |
9421025 | Hawkins et al. | Aug 2016 | B2 |
9433428 | Hakala et al. | Sep 2016 | B2 |
9642673 | Adams et al. | May 2017 | B2 |
9730715 | Adams | Aug 2017 | B2 |
9993292 | Adams | Jun 2018 | B2 |
9999788 | Gattiker et al. | Jun 2018 | B2 |
10226265 | Ku et al. | Mar 2019 | B2 |
10765440 | Tozzi | Sep 2020 | B2 |
20010044596 | Jaafar | Nov 2001 | A1 |
20020045890 | Celliers et al. | Apr 2002 | A1 |
20020077643 | Rabiner et al. | Jun 2002 | A1 |
20020077653 | Hudson et al. | Jun 2002 | A1 |
20020177889 | Brisken et al. | Nov 2002 | A1 |
20030004434 | Greco et al. | Jan 2003 | A1 |
20030088262 | Bonnette et al. | May 2003 | A1 |
20030176873 | Chernenko et al. | Sep 2003 | A1 |
20030229370 | Miller | Dec 2003 | A1 |
20040006333 | Arnold et al. | Jan 2004 | A1 |
20040010249 | Truckai et al. | Jan 2004 | A1 |
20040044308 | Naimark et al. | Mar 2004 | A1 |
20040097963 | Seddon | May 2004 | A1 |
20040097996 | Rabiner et al. | May 2004 | A1 |
20040162508 | Uebelacker | Aug 2004 | A1 |
20040193046 | Nash et al. | Sep 2004 | A1 |
20040254570 | Hadjicostis et al. | Dec 2004 | A1 |
20050015953 | Keidar | Jan 2005 | A1 |
20050021013 | Visuri et al. | Jan 2005 | A1 |
20050059965 | Eberl et al. | Mar 2005 | A1 |
20050075662 | Pedersen et al. | Apr 2005 | A1 |
20050090888 | Hines et al. | Apr 2005 | A1 |
20050113722 | Schultheiss | May 2005 | A1 |
20050113822 | Fuimaono et al. | May 2005 | A1 |
20050171527 | Bhola | Aug 2005 | A1 |
20050228372 | Truckai et al. | Oct 2005 | A1 |
20050245866 | Azizi | Nov 2005 | A1 |
20050251131 | Lesh | Nov 2005 | A1 |
20060004286 | Chang et al. | Jan 2006 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060085054 | Zikorus | Apr 2006 | A1 |
20060184076 | Gill | Aug 2006 | A1 |
20060190022 | Beyar et al. | Aug 2006 | A1 |
20070016112 | Schultheiss et al. | Jan 2007 | A1 |
20070088380 | Hirszowicz et al. | Apr 2007 | A1 |
20070129667 | Tiedtke et al. | Jun 2007 | A1 |
20070239082 | Schultheiss et al. | Oct 2007 | A1 |
20070239253 | Jagger et al. | Oct 2007 | A1 |
20070244423 | Zumeris et al. | Oct 2007 | A1 |
20070255270 | Carney | Nov 2007 | A1 |
20070282301 | Segalescu et al. | Dec 2007 | A1 |
20070299481 | Syed et al. | Dec 2007 | A1 |
20080097251 | Babaev | Apr 2008 | A1 |
20080188913 | Stone et al. | Aug 2008 | A1 |
20090041833 | Bettinger et al. | Feb 2009 | A1 |
20090177085 | Maxwell et al. | Jul 2009 | A1 |
20090247945 | Levit et al. | Oct 2009 | A1 |
20090254114 | Hirszowicz et al. | Oct 2009 | A1 |
20090312768 | Hawkins | Dec 2009 | A1 |
20100016862 | Hawkins et al. | Jan 2010 | A1 |
20100036294 | Mantell et al. | Feb 2010 | A1 |
20100094209 | Drasler et al. | Apr 2010 | A1 |
20100114020 | Hawkins et al. | May 2010 | A1 |
20100114065 | Hawkins et al. | May 2010 | A1 |
20100121322 | Swanson | May 2010 | A1 |
20100305565 | Truckai | Dec 2010 | A1 |
20110034832 | Cioanta et al. | Feb 2011 | A1 |
20110118634 | Golan | May 2011 | A1 |
20110166570 | Hawkins et al. | Jul 2011 | A1 |
20110208185 | Diamant | Aug 2011 | A1 |
20110257523 | Hastings et al. | Oct 2011 | A1 |
20110295227 | Hawkins et al. | Dec 2011 | A1 |
20120071889 | Mantell et al. | Mar 2012 | A1 |
20120095461 | Herscher et al. | Apr 2012 | A1 |
20120116289 | Hawkins et al. | May 2012 | A1 |
20120203255 | Hawkins et al. | Aug 2012 | A1 |
20120221013 | Hawkins et al. | Aug 2012 | A1 |
20130030431 | Adams | Jan 2013 | A1 |
20130030447 | Adams | Jan 2013 | A1 |
20130116714 | Adams et al. | May 2013 | A1 |
20130150874 | Kassab | Jun 2013 | A1 |
20130158453 | Brouillette et al. | Jun 2013 | A1 |
20140005576 | Adams | Jan 2014 | A1 |
20140039513 | Hakala | Feb 2014 | A1 |
20140046229 | Hawkins et al. | Feb 2014 | A1 |
20140052145 | Adams et al. | Feb 2014 | A1 |
20140052147 | Hakala et al. | Feb 2014 | A1 |
20140074111 | Hakala et al. | Mar 2014 | A1 |
20140074113 | Hakala et al. | Mar 2014 | A1 |
20140214061 | Adams et al. | Jul 2014 | A1 |
20140243820 | Adams et al. | Aug 2014 | A1 |
20140243847 | Hakala et al. | Aug 2014 | A1 |
20140288570 | Adams | Sep 2014 | A1 |
20150073430 | Hakala et al. | Mar 2015 | A1 |
20150238208 | Adams et al. | Aug 2015 | A1 |
20150238209 | Hawkins et al. | Aug 2015 | A1 |
20150320432 | Adams | Nov 2015 | A1 |
20160151081 | Adams et al. | Jun 2016 | A1 |
20160183957 | Hakala et al. | Jun 2016 | A1 |
20160184570 | Grace et al. | Jun 2016 | A1 |
20160324534 | Hawkins et al. | Nov 2016 | A1 |
20160331389 | Hakala et al. | Nov 2016 | A1 |
20170135709 | Nguyen et al. | May 2017 | A1 |
20170231649 | Rabiner et al. | Aug 2017 | A1 |
20170311965 | Adams | Nov 2017 | A1 |
20180098779 | Betelia et al. | Apr 2018 | A1 |
20180360482 | Nguyen | Dec 2018 | A1 |
20190150960 | Nguyen et al. | May 2019 | A1 |
20190254692 | Hakala et al. | Aug 2019 | A1 |
20210085348 | Nguyen et al. | Mar 2021 | A1 |
Number | Date | Country |
---|---|---|
2009313507 | Nov 2014 | AU |
1269708 | Oct 2000 | CN |
101043914 | Sep 2007 | CN |
102057422 | May 2011 | CN |
102271748 | Dec 2011 | CN |
102355856 | Feb 2012 | CN |
102765785 | Nov 2012 | CN |
3038445 | May 1982 | DE |
202006014285 | Dec 2006 | DE |
0442199 | Aug 1991 | EP |
0571306 | Nov 1993 | EP |
0623360 | Nov 1994 | EP |
0647435 | Apr 1995 | EP |
2253884 | Nov 2010 | EP |
2359764 | Aug 2011 | EP |
2362798 | Apr 2014 | EP |
60-191353 | Dec 1985 | JP |
62-99210 | Jun 1987 | JP |
62-275446 | Nov 1987 | JP |
3-63059 | Mar 1991 | JP |
6-125915 | May 1994 | JP |
7-47135 | Feb 1995 | JP |
8-89511 | Apr 1996 | JP |
10-99444 | Apr 1998 | JP |
10-314177 | Dec 1998 | JP |
10-513379 | Dec 1998 | JP |
2002-538932 | Nov 2002 | JP |
2004-81374 | Mar 2004 | JP |
2004-357792 | Dec 2004 | JP |
2005-501597 | Jan 2005 | JP |
2005-95410 | Apr 2005 | JP |
2005-515825 | Jun 2005 | JP |
2006-516465 | Jul 2006 | JP |
2007-532182 | Nov 2007 | JP |
2008-506447 | Mar 2008 | JP |
2011-513694 | Apr 2011 | JP |
2011-520248 | Jul 2011 | JP |
2011-524203 | Sep 2011 | JP |
2011-528963 | Dec 2011 | JP |
2012-505050 | Mar 2012 | JP |
2012-508042 | Apr 2012 | JP |
6029828 | Nov 2016 | JP |
6081510 | Feb 2017 | JP |
199203975 | Mar 1992 | WO |
199624297 | Aug 1996 | WO |
199900060 | Jan 1999 | WO |
199902096 | Jan 1999 | WO |
200056237 | Sep 2000 | WO |
WO-2000051502 | Sep 2000 | WO |
2004069072 | Aug 2004 | WO |
WO-2005034793 | Apr 2005 | WO |
2005099594 | Oct 2005 | WO |
2006006169 | Jan 2006 | WO |
2006127158 | Nov 2006 | WO |
2007088546 | Aug 2007 | WO |
2007149905 | Dec 2007 | WO |
2009121017 | Oct 2009 | WO |
2009126544 | Oct 2009 | WO |
2009152352 | Dec 2009 | WO |
2010014515 | Feb 2010 | WO |
2010014515 | Feb 2010 | WO |
2010054048 | May 2010 | WO |
2011094111 | Aug 2011 | WO |
2011143468 | Nov 2011 | WO |
2012025833 | Mar 2012 | WO |
2013059735 | Apr 2013 | WO |
2015017499 | Feb 2015 | WO |
2016109739 | Jul 2016 | WO |
Entry |
---|
Advisory Action received for U.S. Appl. No. 13/615,107, dated Nov. 6, 2015, 3 pages. |
Advisory Action received for U.S. Appl. No. 12/482,995, dated Jun. 2, 2014, 3 pages. |
Advisory Action received for U.S. Appl. No. 12/482,995, dated Sep. 29, 2011, 2 pages. |
Advisory Action received for U.S. Appl. No. 12/581,295, dated Jul. 3, 2014, 3 pages. |
Advisory Action received for U.S. Appl. No. 13/049,199, dated Jun. 7, 2012, 3 pages. |
Advisory Action received for U.S. Appl. No. 13/267,383, dated Jan. 6, 2014, 4 pages. |
Bom et al., “Intra-arterial Ultrasonic Imaging for Recanalization by Spark Erosion”, Ultrasound in Medicine & Biology, vol. 14, No. 4, 1988, pp. 257-261. |
Cleveland et al., “The Physics of Shock Wave Lithotripsy”, Extracorporeal Shock Wave Lithotripsy Part IV, Chapter 38, 2012, pp. 317-332. |
Connors et al., “Renal Nerves Mediate Changes in Contralateral Renal Blood Flow after Extracorporeal Shockwave Lithotripsy”, Nephron Physiol, vol. 95, 2003, pp. 67-75. |
Decision of Appeals Notice received for Japanese Patent Application No. 2011-534914, dated Oct. 17, 2016., 2 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Decision to Grant received for European Patent Application No. 13756766.5, dated May 27, 2016, 2 pages. |
Decision to Grant received for European Patent Application No. 09825393.3, dated Mar. 13, 2014, 2 pages. |
Decision to Grant received for Japanese Patent Application No. 2011-513694, dated Oct. 7, 2014, 3 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Extended European Search Report (includes Supplementary European Search Report and Search Opinion) received for European Patent Application No. 09763640.1, dated Oct. 10, 2013, 5 pages. |
Extended European Search Report and Search Opinion received for European Patent Application No. 09825393.3, dated Feb. 28, 2013, 6 pages. |
Extended European Search Report received for European Patent Application No. 13827971.6, dated Apr. 12, 2016, 8 pages. |
Final Office Action received for U.S. Appl. No. 12/482,995, dated Jul. 22, 2011, 14 pages. |
Final Office Action received for U.S. Appl. No. 12/501,619, dated Feb. 21, 2012, 12 pages. |
Final Office Action received for U.S. Appl. No. 12/611,997, dated Dec. 11, 2012, 9 pages. |
Final Office Action received for U.S. Appl. No. 12/611,997, dated Nov. 10, 2011, 15 pages. |
Final Office Action received for U.S. Appl. No. 13/049,199, dated Apr. 4, 2012, 10 pages. |
Final Office Action received for U.S. Appl. No. 13/207,381, dated Nov. 2, 2012, 7 pages. |
Final Office Action received for U.S. Appl. No. 14/271,342 dated Feb. 27, 2015, 7 pages. |
Final Office Action received for U.S. Appl. No. 12/482,995, dated Feb. 20, 2014, 11 pages. |
Final Office Action received for U.S. Appl. No. 12/581,295, dated Jun. 5, 2014, 14 pages. |
Final Office Action received for U.S. Appl. No. 12/611,997, dated Oct. 24, 2013, 10 pages. |
Final Office Action received for U.S. Appl. No. 13/049,199 dated Aug. 11, 2014, 8 pages. |
Final Office Action received for U.S. Appl. No. 13/207,381, dated Nov. 7, 2013, 7 pages. |
Final Office Action received for U.S. Appl. No. 13/267,383, dated May 28, 2015, 12 pages. |
Final Office Action received for U.S. Appl. No. 13/267,383, dated Oct. 25, 2013, 8 pages. |
Final Office Action received for U.S. Appl. No. 13/534,658, dated Aug. 23, 2016, 11 pages. |
Final Office Action received for U.S. Appl. No. 13/615,107 dated Sep. 1, 2015, 9 pages. |
Final Office Action received for U.S. Appl. No. 13/646,570, dated Dec. 23, 2014, 10 pages. |
Final Office Action received for U.S. Appl. No. 14/229,735, dated Aug. 27, 2015, 7 pages. |
Final Office Action received for U.S. Appl. No. 14/273,063, dated Dec. 28, 2016, 11 pages. |
Final Office Action received for U.S. Appl. No. 14/660,539, dated Aug. 3, 2017, 11 pages. |
Gambihler et al., “Permeabilization of the Plasma Membrane of LI210 Mouse Leukemia Cells Using Lithotripter Shock Waves”, The Journal of Membrane Biology, vol. 141, 1994, pp. 267-275. |
Grassi et al., “Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation”, Curr Hypertens Rep vol. 14, 2012, pp. 567-572. |
Intention to Grant received for European Patent Application No. 13756766.5, dated Jan. 8, 2016, 5 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2009/047070, dated Dec. 23, 2010, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2009/063354, dated May 19, 2011, 6 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2011/047070, dated Feb. 21, 2013, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/023172, dated Aug. 15, 2013, 6 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/063925, dated May 22, 2014, 12 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/031805, dated Feb. 19, 2015, 11 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/039987, dated Nov. 20, 2014, 11 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/048277, dated Jan. 8, 2015, 9 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/055431, dated Feb. 26, 2015, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2013/059533 dated Mar. 26, 2015, 10 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/029088, dated Nov. 17, 2016, 8 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US2018/034855, dated Aug. 23, 2018, 13 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/031805 dated May 20, 2013, 13 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/039987, dated Sep. 23, 2013, 15 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/048277, dated Oct. 2, 2013, 14 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/055431, dated Nov. 12, 2013, 9 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/059533, dated Nov. 7, 2013, 14 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/029088, dated Jul. 16, 2015, 13 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/060817, dated Feb. 20, 2017, 13 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/035750, dated Aug. 1, 2019, 21 pages. |
International Search Report received for PCT Patent Application No. PCT/US2009/047070, dated Jan. 19, 2010, 4 pages. |
International Search Report received for PCT Patent Application No. PCT/US2009/063354, dated Jun. 11, 2010, 3 pages. |
International Search Report received for PCT Patent Application No. PCT/US2012/023172, dated Sep. 28, 2012, 3 pages. |
International Written Opinion received for PCT Patent Application No. PCT/US2009/063354, dated Jun. 11, 2010, 4 pages. |
International Written Opinion received for PCT Patent Application No. PCT/US2011/047070, dated May 1, 2012, 5 pages. |
Kodama et al., “Shock Wave-mediated Molecular Delivery into Cells”, Biochimica et Biophysica Acta vol. 1542, 2002, pp. 186-194. |
Lauer et al., “Shock Wave Permeabilization as a New Gene Transfer Method”, Gene Therapy vol. 4, 1997, pp. 710-715. |
Non-Final Office Action received for U.S. Appl. No. 12/482,995, dated Aug. 13, 2014, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/482,995, dated Jul. 12, 2013, 11 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/611,997, dated Nov. 26, 2014, 8 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/207,381, dated Nov. 25, 2014, 5 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/465,264, dated Oct. 29, 2014, 13 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/646,570, dated Oct. 29, 2014, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/079,463, dated Mar. 4, 2014, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/482,995, dated Feb. 11, 2011, 27 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/501,619, dated Jan. 28, 2014, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/501,619, dated Nov. 3, 2011, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/581,295, dated Jan. 15, 2015, 14 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/581,295, dated Mar. 10, 2014, 11 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/611,997, dated Apr. 8, 2013, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/611,997, dated Aug. 24, 2012, 11 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/611,997, dated Feb. 13, 2014, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 12/611,997, dated Jun. 21, 2011, 13 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/049,199, dated Dec. 12, 2011, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/049,199, dated Feb. 4, 2014, 8 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/207,381, dated Feb. 22, 2013, 7 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/207,381, dated Feb. 25, 2014, 8 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/207,381, dated Jun. 12, 2012, 6 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/267,383, dated Feb. 25, 2015, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/465,264, dated Dec. 23, 2014, 13 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/534,658, dated Mar. 11, 2016, 12 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/615,107, dated Apr. 24, 2015, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/646,583, dated Oct. 31, 2014, 8 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/061,554, dated Mar. 12, 2014, 14 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/218,858, dated Mar. 30, 2016, 13 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/271,276, dated Aug. 4, 2014, 7 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/271,342, dated Sep. 2, 2014, 6 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/273,063, dated Jun. 3, 2016, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/515,130, dated Jan. 14, 2016, 16 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/660,539, dated Nov. 24, 2017, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/693,155, dated Jan. 15, 2016, 6 pages. |
Non-Final Office Action received for U.S. Appl. No. 15/474,885, dated Oct. 5, 2017, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 15/652,070, dated Jan. 11, 2019, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/660,539, dated Mar. 6, 2017, 14 pages. |
Notice of Acceptance received for Australian Patent Application No. 2009257368, dated Aug. 28, 2014, 2 pages. |
Notice of Acceptance received for Australian Patent Application No. 2009313507, dated Nov. 17, 2014, 2 pages. |
Notice of Allowance received for Canadian Patent Application No. 2,727,429, dated May 26, 2015, 1 page. |
Notice of Allowance received for Canadian Patent Application No. 2,779,600, dated Jul. 7, 2017, 1 page. |
Notice of Allowance received for Chinese Patent Application No. 201380033808.3, dated Dec. 29, 2016, 4 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Notice of Allowance received for Chinese Patent Application No. 201380041656.1, dated Mar. 3, 2017, 4 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Notice of Allowance received for Japanese Patent Application No. 2015-036444, dated Jan. 13, 2017, 3 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Notice of Allowance received for Japanese Patent Application No. 2015-520522, dated Feb. 23, 2017, 3 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Notice of Allowance received for U.S. Appl. No. 15/652,070, dated May 21, 2019, 8 pages. |
Notice of Allowance received for U.S. Appl. No. 12/581,295, dated Jul. 10, 2015, 15 pages. |
Notice of Allowance received for U.S. Appl. No. 12/581,295, dated Jul. 29, 2015, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 12/611,997, dated Apr. 15, 2015, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/207,381, dated Apr. 14, 2015, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/465,264, dated May 8, 2015, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/957,276, dated Aug. 28, 2015, 9 pages. |
Notice of Allowance received for U.S. Appl. No. 14/271,276, dated Feb. 25, 2015, 8 pages. |
Notice of Allowance received for U.S. Appl. No. 12/482,995, dated Dec. 24, 2014, 6 pages. |
Notice of Allowance received for U.S. Appl. No. 13/049,199, dated Dec. 15, 2014, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/049,199, dated Jan. 13, 2015, 4 pages. |
Notice of Allowance received for U.S. Appl. No. 13/534,658, dated Jan. 5, 2017, 6 pages. |
Notice of Allowance received for U.S. Appl. No. 13/534,658, dated Jan. 18, 2017, 4 pages. |
Notice of Allowance received for U.S. Appl. No. 13/646,570, dated Mar. 11, 2015, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/777,807, dated May 19, 2015, 13 pages. |
Notice of Allowance received for U.S. Appl. No. 13/831,543, dated Oct. 8, 2014, 14 pages. |
Notice of Allowance received for U.S. Appl. No. 14/061,554, dated Apr. 25, 2014, 8 pages. |
Notice of Allowance received for U.S. Appl. No. 14/079,463, dated Apr. 1, 2014, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 14/218,858, dated Aug. 26, 2016, 8 pages. |
Notice of Allowance received for U.S. Appl. No. 14/271,342, dated Mar. 13, 2015, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 14/273,063, dated Apr. 12, 2017., 7 pages. |
Notice of Allowance received for U.S. Appl. No. 14/515,130, dated May 2, 2016, 8 pages. |
Notice of Allowance received for U.S. Appl. No. 14/515,130, dated May 25, 2016, 3 pages. |
Notice of Allowance received for U.S. Appl. No. 14/660,539, dated Apr. 6, 2018, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 14/693,155, dated Apr. 26, 2016, 9 pages. |
Notice of Allowance received for U.S. Appl. No. 15/474,885, dated Feb. 14, 2018, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 13/615,107, dated Dec. 31, 2015, 10 pages. |
Office Action received for Australian Patent Application No. 2009257368, dated Apr. 28, 2014, 4 pages. |
Office Action received for Australian Patent Application No. 2009257368, dated Jul. 31, 2013, 4 pages. |
Office Action received for Australian Patent Application No. 2009313507, dated Nov. 13, 2013, 3 pages. |
Office Action received for Australian Patent Application No. 2013284490, dated Jun. 5, 2017, 4 pages. |
Office Action received for Australian Patent Application No. 2013300176, dated Nov. 10, 2016, 2 pages. |
Office Action received for Canadian Patent Application No. 2,727,429, dated Apr. 14, 2015, 4 pages. |
Office Action received for Canadian Patent Application No. 2,779,600, dated Jan. 4, 2016, 6 pages. |
Office Action received for Canadian Patent Application No. 2,779,600, dated Oct. 19, 2016, 3 pages. |
Office Action received for Chinese Patent Application No. 200980153687.x, dated Dec. 26, 2012, 11 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Office Action received for Chinese Patent Application No. 200980153687.x, dated Jul. 11, 2013, 11 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Office Action received for Chinese Patent Application No. 201380033808.3, dated Jul. 5, 2016., 9 pages (3 pages of English Translation and 6 pages of Official copy). |
Office Action received for Chinese Patent Application No. 201380041656.1, dated Jul. 5, 2016., 9 pages (4 pages of English Translation and 5 pages of Official copy). |
Office Action received for Chinese Patent Application No. 201380042887.4, dated Aug. 8, 2016, 9 pages (4 pages of English Translation and 5 pages of Official copy). |
Office Action received for European Patent Application No. 09763640.1, dated Dec. 2, 2016, 4 pages. |
Office Action received for Japanese Patent Application No. 2011-513694, dated Aug. 27, 2013, 6 pages (3 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2011-513694, dated Jun. 10, 2014, 4 pages total (2 pages of Official copy and 2 pages of English Translation) . |
Office Action received for Japanese Patent Application No. 2011-534914, dated Jan. 13, 2015, 9 pages(7 pages of English Translation and 2 pages of Official copy. |
Office Action received for Japanese Patent Application No. 2011-534914, dated Jul. 15, 2014, 3 pages (1 page of English Translation and 2 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2011-534914, dated May 10, 2016, 10 pages (4 pages of Official copy and 6 pages of English Translation). |
Office Action received for Japanese Patent Application No. 2011-534914, dated Oct. 1, 2013, 5 pages (2 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2014-158517, dated Feb. 15, 2017, 8 pages (5 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2014-158517, dated Jun. 22, 2017., 14 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Office Action received for Japanese Patent Application No. 2014-158517, dated May 19, 2015, 5 pages (2 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2015-036444, dated Feb. 23, 2016, 3 pages of English Translation only. |
Office Action received for Japanese Patent Application No. 2015-526523, dated Jan. 25, 2017, 8 pages (5 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2016-143049, dated Apr. 24, 2017., 5 pages (2 pages of English Translation and 3 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2015-036444, dated Sep. 14, 2016, 5 pages (3 pages of English Translation and 2 pages of Official copy). |
Office Action received for Japanese Patent Application No. 2016-094326, dated Dec. 2, 2016, 4 pages (2 pages of English Translation and 2 pages Official copy). |
Office Action received for Japanese Patent Application No. 2016-094326, dated Jul. 6, 2017, 2 pages (Official copy only) (See Communication under 37 CFR § 1.98(a) (3)). |
Rosenschein et al., “Shock-wave Thrombus Ablation, a New Method for Noninvasive Mechanical Thrombolysis”, The American Journal of Cardiology, vol. 70, Nov. 15, 1992, pp. 1358-1361. |
Sakes et al., “Crossing Total Occlusions: Navigating Towards Recanalization”, Cardiovascular Engineering and Technology, vol. 7, No. 2, Jun. 2016, pp. 103-117. |
Written Opinion received for PCT Patent Application No. PCT/US2012/023172, dated Sep. 28, 2012, 4 pages. |
Written Opinion received for PCT Patent Application No. PCT/US2009/047070, dated Jan. 19, 2010, 5 pages. |
Zhong et al., “Transient Oscillation of Cavitation Bubbles Near Stone Surface During Electrohydraulic Lithotripsy”, Journal of Endourology, vol. 11, No. 1, Feb. 1997, pp. 55-61. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/035750, dated Dec. 30, 2020, 11 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/051551, dated Jan. 11, 2021, 16 pages. |
U.S. Appl. No. 17/025,866, filed Sep. 18, 2020, titled “System for Treating Thrombus in Body Lumens,” (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii)). |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/071938 dated Jan. 18, 2022, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20190388110 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
62688110 | Jun 2018 | US |